Bone Strength is the Fastest Growing Segment Fueling the Growth of Postmenopausal Osteoporosis Market
The global Postmenopausal
Osteoporosis Market is estimated to be valued at US$ 4,747.9 Mn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period
2023 to 2030, as highlighted in a new report published by Coherent Market
Insights.
Market Overview:
Postmenopausal osteoporosis is a condition where bones become brittle and
fragile from loss of tissue, typically in the spine, hips and wrists. Drugs
associated with postmenopausal osteoporosis help increase bone mineral density
and reduce the risk of fractures.
Market key trends:
One of the key trends fueling the growth of this market is the ongoing research
into drug combinations for postmenopausal osteoporosis treatment. Several
pharmaceutical companies are conducting clinical trials to test the safety and
efficacy of combining different drug classes like bisphosphonates with
parathyroid hormone analogs to develop more effective treatment regimens. If
proven successful, such drug combinations could receive regulatory approvals
and change the standard of care, driving significant growth in the market.
Segment Analysis
The global postmenopausal osteoporosis market is segmented into type and route
of administration. Based on type, the market is bifurcated into
bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin,
parathyroid hormone therapy, and others. The bisphosphonates segment currently
dominates the market due to high efficacy, low risk of side effects, and
extensive usage of bisphosphonate drugs such as alendronate and risedronate for
osteoporosis treatment.
Based on route of administration, the market is segmented into oral and
parenteral. The oral segment accounts for the largest share due to ease of
administration.
Key Takeaways
The Global
Postmenopausal Osteoporosis Market Size was valued at US$ 4,747.9 million in 2023 and is
expected to witness high growth, exhibiting CAGR of 4.4% over the forecast period due to increasing geriatric
population and the subsequent rise in osteoporosis cases.
Regional analysis:
North America accounted for
the largest share of the global market in 2023 due to high awareness about
osteoporosis and well-developed healthcare infrastructure in the region. Asia
Pacific is expected to grow at the highest CAGR during the forecast period.
This can be attributed to rising cases of osteoporosis due to changing
lifestyles in countries like China and India.
Key players analysis:
Key players operating in the
postmenopausal osteoporosis market are Pfizer Inc., F. Hoffmann-La Roche Ltd,
Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC,
Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun
Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras
Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING,
Amgen, Gedeon Richter Plc. Enzene Biosciences, Samsung BioepisL Radius Health,
Inc., Alvotech, and AryoGen Pharmed.
For More Insights, Read: https://www.newsstatix.com/postmenopausal-osteoporosis-market-size-share-and-growth-forecast-2023-2030/
Comments
Post a Comment